Viewing Study NCT00217971



Ignite Creation Date: 2024-05-05 @ 12:01 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00217971
Status: COMPLETED
Last Update Posted: 2019-04-24
First Post: 2005-09-16

Brief Title: Dronabinol Treatment for Marijuana Addiction
Sponsor: New York State Psychiatric Institute
Organization: New York State Psychiatric Institute

Study Overview

Official Title: A Randomized Double-Blind Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction
Status: COMPLETED
Status Verified Date: 2019-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MARINOL
Brief Summary: The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal
Detailed Description: Marijuana addiction is associated with significant withdrawal symptoms including anxiety irritability bodily discomfort and insomnia The purpose of this study is to determine the effectiveness of dronabinol in reducing withdrawal symptoms

During this twelve-week double-blind placebo-controlled study study visits will occur twice each week During study visits participants will receive either placebo or medication Throughout the study all participants will receive individualized psychotherapy sessions At each study visit vital signs self-report ratings and urine samples will be collected Participants will have a follow-up evaluation at month 6

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
P50DA009236 NIH None None
P50DA009236-11 NIH None None
DPMC US NIH GrantContract None httpsreporternihgovquickSearchP50DA009236-11